drugset / Trial / NCT05639257
Treatment of Myotonia - Lamotrigine Versus Namuscla
Unknown
32 enrolled
Grete Andersen, MD
Danish Region · collabGCP-Copenhagen · collabLupin Atlantis Holdings S.A. · collabRegion Capital Denmark · collabZiteLab · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
In this clinical study, the aim is to investigate whether there is a difference in treatment of myotonia using two drugs. A difference there can justify the significantly higher cost when treated by Namuscla versus Lamotrigine. According to the current corona pandemic, the investigators designed an app to use for data collection in the study. The app also ensures that patients who live far from the clinic more easily can participate.
Timeline
- Start
- 2022-12-05
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lamotrigine | Small molecule | 100 mg | — |
| Comparator | Mexiletine | Small molecule | 167 mg | — |